Home > Boards > US Listed > Biotechs > Applied DNA Sciences Inc. (APDN)

Applied DNA Receives Extension from Nasdaq

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
RodeKroet Member Profile
 
Followed By 4
Posts 1,278
Boards Moderated 1
Alias Born 11/10/15
160x600 placeholder
Successful DNA Tagging of Leather at One of the World’s Largest Tanneries Business Wire - 11/12/2019 9:03:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/8/2019 4:17:47 PM
Applied DNA Sciences Announces Appointment of Scott L. Anchin to Board of Directors  Business Wire - 11/8/2019 3:22:00 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 11/8/2019 3:15:19 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 11/1/2019 5:22:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/31/2019 4:07:01 PM
Applied DNA Sciences Announces 1-For-40 Reverse Stock Split Business Wire - 10/31/2019 1:00:00 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 10/25/2019 4:28:35 PM
Applied DNA Receives Notice of Allowance on Patent Protecting its CertainT® Platform in Cellulosic Fibers and Materials Business Wire - 10/22/2019 8:30:00 AM
Applied DNA Partners with Molecular Isotope Technologies to Elevate CertainT® for Brand Assurance and Provenance Business Wire - 10/16/2019 5:30:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/8/2019 4:02:30 PM
Molecular Tagging of Pharmaceutical Excipients Utilizing Applied DNA’s Technology Published in Peer-Reviewed Journal Business Wire - 10/4/2019 5:00:00 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 10/3/2019 4:03:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/3/2019 6:32:21 AM
Applied DNA Receives Extension from Nasdaq Business Wire - 10/3/2019 5:00:00 AM
LineaRx’s iCTC Platform for Isolation of Circulating Tumor Cells Shows Superior Correlation over PSA as a Biomarker in Pros... Business Wire - 10/1/2019 8:30:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 9/26/2019 5:23:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/25/2019 4:03:37 PM
Applied DNA Receives $1 Million Order to Supply SigNature® T Molecular Taggant for 2019-2020 Cotton Harvest Season Business Wire - 9/24/2019 9:00:00 AM
LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction Business Wire - 9/19/2019 4:00:00 AM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 9/18/2019 5:30:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/17/2019 4:02:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 4:59:05 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 9/16/2019 4:14:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 4:04:11 PM
RodeKroet   Thursday, 10/03/19 05:07:29 AM
Re: None
Post # of 56794 
Applied DNA Receives Extension from Nasdaq
STONY BROOK, N.Y., October 3, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”) (“we,” “us,” “our,” the “Company”), a leader in large-scale PCR-based DNA manufacturing, today announced that the Nasdaq Hearings Panel (the “Panel”) , has granted Applied DNA’s request for an extension through December 31, 2019, to comply with all applicable criteria for continued listing of the Company’s securities on The Nasdaq Capital Market (“Nasdaq”), including the minimum $1.00 bid price and $2.5 million stockholders’ equity requirements. During the extension, Applied DNA’s securities will remain listed on Nasdaq.

“We are appreciative of the Nasdaq Hearings Panel’s decision to grant us our requested extension to evidence compliance with all applicable requirements for continued listing on Nasdaq. The management team and Board of Directors place the highest priority on our continued listing, and we want to assure all stakeholders that we continue to work diligently on executing on our compliance plan,” stated Dr. James A. Hayward, president and CEO of Applied DNA.

The Company is diligently working to comply with the minimum $1.00 bid price and $2.5 million stockholders’ equity requirements; however, there can be no assurance that the Company will be able to regain compliance with the applicable listing criteria within the period granted by the Panel.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist